UNLABELLED: Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is a rare tumor typically affecting young women. It is an aggressive malignancy with a poor prognosis and few long-term survivors. OBJECTIVE: Investigate the outcome of patients with SCCOHT. METHOD: Data were collected for patients with SCCOHT treated in Australia, Canada and Europe. Information included stage, surgery, chemotherapy, radiotherapy, recurrence and survival. RESULTS: The median follow-up is 13 months for all patients and 35.5 months in surviving patients. Ten patients had FIGO stage I tumors, six stage III tumors and one stage unknown. All underwent surgical resection. Adjuvant platinum-based chemotherapy was given to all patients. Seven received adjuvant radiotherapy with either pelvic and para-aortic radiotherapy, average dose 46.5 Gy (40 Gy/25# - 50.4 Gy/23#), or pelvic and whole abdominal radiotherapy, average dose 45 Gy to pelvis and 25 Gy (22.5 Gy/22# - 30 Gy/25#) to abdomen. The median survival for stage I tumors was not reached and was 6 months for stage III tumors. For the ten patients with stage I tumors: six received adjuvant radiotherapy with five alive and disease-free; four received no adjuvant radiotherapy with one alive and disease-free, while three have relapsed with one alive and disease-free after resection. Of the seven patients with stage III or unknown stage tumors, all but one have died. Recurrences were most frequent in the pelvis and the abdomen. Patients receiving salvage treatment with chemotherapy and radiotherapy did poorly. CONCLUSION: We advocate a multi-modality treatment approach including surgery, chemotherapy with the addition of radiotherapy either sequentially or concurrently.
UNLABELLED: Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is a rare tumor typically affecting young women. It is an aggressive malignancy with a poor prognosis and few long-term survivors. OBJECTIVE: Investigate the outcome of patients with SCCOHT. METHOD: Data were collected for patients with SCCOHT treated in Australia, Canada and Europe. Information included stage, surgery, chemotherapy, radiotherapy, recurrence and survival. RESULTS: The median follow-up is 13 months for all patients and 35.5 months in surviving patients. Ten patients had FIGO stage I tumors, six stage III tumors and one stage unknown. All underwent surgical resection. Adjuvant platinum-based chemotherapy was given to all patients. Seven received adjuvant radiotherapy with either pelvic and para-aortic radiotherapy, average dose 46.5 Gy (40 Gy/25# - 50.4 Gy/23#), or pelvic and whole abdominal radiotherapy, average dose 45 Gy to pelvis and 25 Gy (22.5 Gy/22# - 30 Gy/25#) to abdomen. The median survival for stage I tumors was not reached and was 6 months for stage III tumors. For the ten patients with stage I tumors: six received adjuvant radiotherapy with five alive and disease-free; four received no adjuvant radiotherapy with one alive and disease-free, while three have relapsed with one alive and disease-free after resection. Of the seven patients with stage III or unknown stage tumors, all but one have died. Recurrences were most frequent in the pelvis and the abdomen. Patients receiving salvage treatment with chemotherapy and radiotherapy did poorly. CONCLUSION: We advocate a multi-modality treatment approach including surgery, chemotherapy with the addition of radiotherapy either sequentially or concurrently.
Authors: Petar Jelinic; Jennifer J Mueller; Narciso Olvera; Fanny Dao; Sasinya N Scott; Ronak Shah; JianJiong Gao; Nikolaus Schultz; Mithat Gonen; Robert A Soslow; Michael F Berger; Douglas A Levine Journal: Nat Genet Date: 2014-03-23 Impact factor: 38.330
Authors: Elizabeth K Lee; Katharine M Esselen; David L Kolin; Larissa J Lee; Ursula A Matulonis; Panagiotis A Konstantinopoulos Journal: JCO Precis Oncol Date: 2020-06-24
Authors: Leora Witkowski; Catherine Goudie; Pilar Ramos; Talia Boshari; Jean-Sebastien Brunet; Anthony N Karnezis; Michel Longy; James A Knost; Emmanouil Saloustros; W Glenn McCluggage; Colin J R Stewart; William P D Hendricks; Heather Cunliffe; David G Huntsman; Patricia Pautier; Douglas A Levine; Jeffrey M Trent; Andrew Berchuck; Martin Hasselblatt; William D Foulkes Journal: Gynecol Oncol Date: 2016-03-19 Impact factor: 5.482
Authors: D Callegaro-Filho; D M Gershenson; A M Nick; M F Munsell; P T Ramirez; P J Eifel; E D Euscher; R M Marques; S M Nicolau; K M Schmeler Journal: Gynecol Oncol Date: 2015-11-04 Impact factor: 5.482
Authors: John J Wallbillich; Alpa M Nick; Pedro T Ramirez; Jack L Watkins; Elizabeth D Euscher; Kathleen M Schmeler Journal: Gynecol Oncol Case Rep Date: 2012-02-13